These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
93 related items for PubMed ID: 2260870
1. [Mechanism of antitumor effect of a benzoylphenylurea derivative, HO-221]. Nakajima T, Okamoto T, Masuda H, Watanabe M, Yokoyama K, Yamada N, Tsukagoshi S, Taguchi T. Gan To Kagaku Ryoho; 1990 Dec; 17(12):2345-51. PubMed ID: 2260870 [Abstract] [Full Text] [Related]
2. [Antitumor effect of a benzoylphenylurea derivative HO-221]. Nakajima T, Masuda H, Okamoto T, Watanabe M, Yokoyama K, Yamada N, Tsukagoshi S, Taguchi T. Gan To Kagaku Ryoho; 1990 Dec; 17(12):2353-9. PubMed ID: 2260871 [Abstract] [Full Text] [Related]
3. [Cross-resistance of HO-221 and various antitumor agents in sublines of mouse leukemia]. Nakajima T, Masuda H, Okamoto T, Watanabe M, Yokoyama K, Yamada N, Fujimoto S, Tsukagoshi S, Taguchi T. Gan To Kagaku Ryoho; 1991 Feb; 18(2):201-9. PubMed ID: 1899547 [Abstract] [Full Text] [Related]
4. Mechanism of tumor cell killing by HO-221, a novel antitumor compound. Nakajima T, Okamoto T, Masuda H, Watanabe M, Yokoyama K, Yamada N, Tsukagoshi S, Taguchi T. Cancer Chemother Pharmacol; 1990 Feb; 27(3):199-204. PubMed ID: 1702366 [Abstract] [Full Text] [Related]
5. Antitumor mechanisms of zinostatin stimalamer (YM881). Tanaka S, Yamamoto M, Numasaki Y. Res Commun Mol Pathol Pharmacol; 1996 May; 92(2):165-76. PubMed ID: 8774070 [Abstract] [Full Text] [Related]
6. [Antitumor activity of HO-221, a derivative of benzoylphenylurea against human cancer xenografts in nude mice]. Fujita F, Fujita M, Inaba H, Sugimoto T, Okuyama Y, Taguchi T. Gan To Kagaku Ryoho; 1991 Oct; 18(13):2255-61. PubMed ID: 1929446 [Abstract] [Full Text] [Related]
7. [Combined effect of HO-221 with various antitumor agents against L 1210 leukemia]. Nakajima T, Masuda H, Okamoto T, Watanabe M, Yokoyama K, Yamada N, Tsukagoshi S, Taguchi T. Gan To Kagaku Ryoho; 1991 Apr; 18(4):555-62. PubMed ID: 2012397 [Abstract] [Full Text] [Related]
8. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide. Burres NS, Clement JJ. Cancer Res; 1989 Jun 01; 49(11):2935-40. PubMed ID: 2720652 [Abstract] [Full Text] [Related]
9. The inhibition of P338 lymphocytic leukemia DNA polymerase alpha activity by cis-diamminedichloroplatinum(II) and related derivatives. Oswald CB, Hall IH. Anticancer Res; 1989 Jun 01; 9(4):915-22. PubMed ID: 2817817 [Abstract] [Full Text] [Related]
10. Cytotoxicity of ribo-and arabinoside boron nucleosides in tissue culture cells. Sood A, Spielvogel BF, Powell WJ, Bastow KF, Miller MC, Hall IH. Anticancer Res; 1994 Jun 01; 14(4A):1483-8. PubMed ID: 7979174 [Abstract] [Full Text] [Related]
11. Redifferentiation of human hepatoma cell induced by 6-(p-chlorophenyl)-3-[1-(p-chlorophenyl)-5-methyl-1 H-1,2,3-triazol-4-yl]-s-triazolo[3,4-b]-1,3,4-thiadiazole (TDZ). Zhang Q, Pan J, Zheng RL, Wang Q. Pharmazie; 2005 May 01; 60(5):378-82. PubMed ID: 15918590 [Abstract] [Full Text] [Related]
12. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Gorczyca W, Gong J, Ardelt B, Traganos F, Darzynkiewicz Z. Cancer Res; 1993 Jul 01; 53(13):3186-92. PubMed ID: 8319228 [Abstract] [Full Text] [Related]
13. Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110. Yoshinari T, Yamada A, Uemura D, Nomura K, Arakawa H, Kojiri K, Yoshida E, Suda H, Okura A. Cancer Res; 1993 Feb 01; 53(3):490-4. PubMed ID: 8381047 [Abstract] [Full Text] [Related]
14. [Antitumor effect and mechanism of a novel multifunctional nucleoside, 3'-ethynylnucleoside, on human cancers]. Tanaka M, Tabata S, Matsuda A, Fukushima M, Eshima K, Sasaki T. Gan To Kagaku Ryoho; 1997 Feb 01; 24(4):476-82. PubMed ID: 9063487 [Abstract] [Full Text] [Related]
15. In vitro antitumor mechanism of a new platinum complex, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato+ ++) platinum(II). Akamatsu K, Endo K, Matsumoto T, Morikawa K, Koizumi M, Mitsui H, Koizumi K. Anticancer Res; 1991 Feb 01; 11(1):151-5. PubMed ID: 2018348 [Abstract] [Full Text] [Related]
16. Antitumor activity on murine tumors of a novel antitumor benzoylphenylurea derivative, HO-221. Nakajima T, Masuda H, Okamoto T, Watanabe M, Yokoyama K, Yamada N, Fujimoto S, Tsukagoshi S, Taguchi T. Cancer Chemother Pharmacol; 1991 Feb 01; 28(5):351-6. PubMed ID: 1914078 [Abstract] [Full Text] [Related]
17. Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. Nishio K, Ishida T, Arioka H, Kurokawa H, Fukuoka K, Nomoto T, Fukumoto H, Yokote H, Saijo N. Anticancer Res; 1996 Feb 01; 16(6B):3387-95. PubMed ID: 9042196 [Abstract] [Full Text] [Related]
18. Antitumor effect of alpha isomer of anordrin in vitro and cell cycle arrest at G1 phase. Weng SM, Xu YP, Xu B. Zhongguo Yao Li Xue Bao; 1994 Jan 01; 15(1):47-50. PubMed ID: 8010085 [Abstract] [Full Text] [Related]
19. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines. Koike M, Koshizuka K, Kawabata H, Yang R, Taub HE, Said J, Uskokovic M, Tsuruoka N, Koeffler HP. Anticancer Res; 1999 Jan 01; 19(3A):1689-97. PubMed ID: 10470102 [Abstract] [Full Text] [Related]
20. Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand. Jiang JD, Denner L, Ling YH, Li JN, Davis A, Wang Y, Li Y, Roboz J, Wang LG, Perez-Soler R, Marcelli M, Bekesi G, Holland JF. Cancer Res; 2002 Nov 01; 62(21):6080-8. PubMed ID: 12414632 [Abstract] [Full Text] [Related] Page: [Next] [New Search]